DEVONIAN HEALTH GROUP INC Stock Price, News & Analysis

Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory disease solutions, has completed a non-brokered private placement raising $2.27 million in gross proceeds. The offering consisted of 15,153,332 units priced at $0.15 per unit, with each unit comprising one subordinate voting share and one warrant.

Each warrant allows holders to purchase one share at $0.20 within a 24-month period. The funds will support working capital needs, corporate overhead, and R&D activities. The securities have a four-month restricted hold period ending December 8, 2025.

Devonian Health Group (OTCQB:DVHGF) reported its Q3 2025 financial results, with revenue increasing 36% year-over-year to $7.36 million. The company recorded a net loss of $0.032 per share, primarily due to a $4.84 million non-cash impairment loss related to the expiration of their DEXLANSOPRAZOLE distribution agreement.

The quarter saw significant management changes with Dr. Andre Boulet appointed as CEO and Luc Gregoire as Executive Vice-President Strategy. The company completed preclinical studies for Thykamine™, exploring new applications in inflammatory diseases, including MASH and fibrosis.

Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory diseases, has announced key leadership changes and stock option grants. Dr. André Boulet has been appointed as Chief Executive Officer, replacing Luc Gregoire who transitions to Executive Vice-President Strategy, effective June 9, 2025. The company also granted stock options totaling 1,288,596 shares at an exercise price of $0.15, valid until June 9, 2035. Of these, 438,596 options were granted to a director and 850,000 to employees. The options follow a vesting schedule with 50.33% immediately exercisable, and the remaining portions vesting over 48 months in equal installments of 12.42% every 12 months.

Devonian Health Group has successfully achieved reinstatement of its common shares trading on the TSX Venture Exchange (TSXV), effective April 30, 2025. This development follows the resolution of a temporary trading suspension.

Key developments:

• The Autorité des marchés financiers (AMF) issued a Failure-to-File Cease Trade Order on April 7, 2025
• The suspension was due to delayed filing of required interim financial documents for the quarter ending January 31, 2025
• Company submitted the required filings on April 15, 2025
• AMF revoked the cease trade order on April 16, 2025

The required submissions included quarterly financial statements, management's discussion and analysis, and related documentation. Trading will resume under the symbols GSD on TSXV and DVHGF on OTCQB. The company has expressed gratitude to shareholders for their patience and reinforced its dedication to maintaining high compliance standards.

Devonian Health Group (OTCQB: DVHGF) reported strong Q2 2025 financial results with revenue soaring 275% year-over-year to $8.28 million, primarily driven by DEXLANSOPRAZOLE distribution agreement. The company posted a net loss of $0.001 per share, improving from $0.01 loss per share in the previous year.

The company's cash position stood at $8.4 million with zero debt, down from $9.9 million at fiscal year start. Notable achievements include Thykamine™'s superior performance in anti-inflammatory studies versus corticosteroids, positive results in MASH mouse model studies, and new provisional patent applications for Thykamine™ in metabolic dysfunction-associated steatohepatitis and as an anti-fibrotic agent.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has received a failure to file cease trade order (FFCTO) from the Autorité des Marchés Financiers (AMF) due to delayed filing of required interim financial documents for the period ended January 31, 2025.

The FFCTO prohibits all trading of company securities in Canada, including trades through the TSX Venture Exchange. The required documents include interim financial statements, management's discussion and analysis, and related filings that were due by April 1, 2025.

Trading suspension became effective April 8, 2025. The company continues normal business operations and will seek FFCTO revocation once the required filings are submitted. Trading reinstatement requires both FFCTO revocation and Exchange approval following a compliance review.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has announced a delay in filing its Q2 2025 financial statements and MD&A beyond the April 1, 2025 deadline. The delay stems from recently discovered errors in previous financial statements that require amendments.

The company identified two key issues in its FY2024 statements:

• An unrecorded current tax expense and liability of $782,273
• An over-accrual of expenses amounting to $245,000

These adjustments result in a net increase of $537,273 to the 's net loss and current liabilities for FY2024, representing 3% of revenues, 4% of total expenses, and 4% of net assets.

Additionally, selling expenses were incorrectly applied against revenues instead of being charged to administrative expenses, requiring reclassifications that will increase reported Distribution Revenues and Administrative Expenses by $1,245,477 and $271,754 for FY2024 and FY2023, respectively. The company expects to file both amended previous statements and current period financials within April 2025.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF), a clinical stage focused on inflammatory disease solutions, held its annual general meeting on March 20, 2025. Shareholders approved several key proposals:

• Election of eight directors including André P. Boulet and Dennis Turpin
• Appointment of MNP LLP as independent auditor for fiscal year ending July 31, 2025
• Amendment to the Option Plan to increase shares reserved for issuance to 20% of outstanding shares
• Renewal of the restricted share unit Rights Plan
• Approval of share consolidation up to 70:1 ratio to potentially broaden investor pool and meet minimum trading requirements for potential U.S. stock exchange listing

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has filed a new patent application for Thykamine™ as an antifibrotic agent. The application is supported by in vivo data demonstrating the potential effectiveness of thylakoid extracts in treating and slowing fibrosis progression, while also down-regulating genes associated with fibrogenesis in various organs and tissues. According to Dr. André P. Boulet, Chief Scientific Officer, this filing aligns with the company's strategy to expand its patent portfolio and broadens Thykamine™'s potential therapeutic applications in treating fibrotic diseases.